This is a proof-and-scale story, not a moonshot. The company already has real demand, shipping products, and visible operating leverage, so the main question is whether auto rollout, bundling, and higher retained economics can persist without breaking
underwriting quality. If that works, the business can look less like a perpetual insurtech experiment and more like a differentiated personal-lines compounder, which supports a solid but not software-level
rerating.